ASX-Dividend-Report-Banner

Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

September 11, 2024 04:25 PM AEST | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue
Image source: Kalkine Media
  • Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA. 

SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the current state of antiviral treatments at the "Disease Prevention and Control Summit 2024." He highlighted the lack of effective therapies for global public health threats like COVID-19, dengue, mpox, HIV/AIDS, and influenza type A (H1N1), and expressed confidence in XAFTY®'s potential to treat all of these.

Clinical results: Effective blood drug concentration of XAFTY® and its capability to treat multiple viral diseases
Clinical results: Effective blood drug concentration of XAFTY® and its capability to treat multiple viral diseases

Mr. Woo noted, "The traditional 'one drug, one disease' approach has been a failure, leaving us vulnerable not only to future pandemics but also to ongoing viral threats such as mpox, dengue, and COVID-19. The key to tackling these public health crises lies in developing 'one drug, multiple targets' antivirals, and XAFTY® is the only solution currently available."

Hyundai Bioscience developed XAFTY® by overcoming two major challenges associated with niclosamide, a compound previously known for its antiviral properties but hindered by poor absorption and short efficacy. Through proprietary drug delivery technology, Hyundai Bioscience has successfully reformulated niclosamide into XAFTY®, a new oral antiviral drug.

Through clinical trials, animal testing, and cell experiments, XAFTY® has proven effectiveness against various viral infections, including those where niclosamide has shown efficacy. The company has successfully demonstrated XAFTY®'s safety and efficacy in treating COVID-19 and is currently undergoing Phase 3 clinical trials with high-risk groups of COVID-19 patients.

Hyundai Bioscience conducted an animal study comparing the efficacy of TAMIFLU® and XAFTY® against H1N1, a strain of influenza A with future pandemic potential. The results showed that XAFTY® considerably reduced influenza virus levels compared to TAMIFLU®. This finding is the first to reveal that XAFTY®, which has already proven effective against COVID-19, also demonstrates in vivo efficacy against respiratory viruses from different families.

Dr. Heung-Jeong Woo of Hyundai Bioscience, during a roundtable discussion following his keynote presentation, stated, "XAFTY® is currently in phase 3 clinical stage for COVID-19, particularly targeting high-risk groups. It has also been confirmed to be effective against mpox and dengue fever, diseases for which there are currently no treatments available despite being public health emergencies. As a result, XAFTY® is the only antiviral capable of treating both mpox and dengue fever at this time. Accordingly, Hyundai Bioscience is in close discussions with countries facing public health crises due to dengue fever and mpox, to expedite the supply of XAFTY® to patients suffering from these diseases."

Hyundai Bioscience is in close talks with several countries facing public health challenges from mpox and dengue to supply XAFTY® swiftly. CEO of Hyundai Bioscience USA, Jason Kim reflected on the event, stating, "This summit has brought international recognition to XAFTY® as the only broad-spectrum antiviral capable of addressing both current and future viral threats.

About Hyundai Bioscience

Hyundai Bioscience is a biotechnology company that develops new drugs based on its novel drug delivery system technologies to deliver active ingredients safely and efficiently to targeted areas of the human body. Founded in 2000, Hyundai Bioscience focuses on repurposing or expanding indications of existing drugs using its proprietary organic-inorganic hybrid technologies. Hyundai Bioscience is a public company listed on KOSDAQ (symbol: 048410) in South Korea.

For more information, please contact Ms. Joobin Jung, Global PR Manager ([email protected]). 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.